Austedo (Deutetrabenazine) Patent Expiration, LOE Window & CMS Spending

Austedo (Deutetrabenazine) by Teva Pharmaceuticals: FDA Orange Book core substance LOE 2034-03-18 (last listed 2038-09-15), 0 AB generics, $1.30B 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTeva Pharmaceuticals
FDA Application & PathwayN208082 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-03-18
Last Listed Patent or Exclusivity Date2038-09-15
Orange Book Patents (*PED Extensions)28 patents (14 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.30B
2024 Medicare Part D Spend$1.07B
2024 Medicaid Spend$236.9M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 22.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.